Brokerages Set Microbot Medical Inc. (NASDAQ:MBOT) Target Price at $6.63

Microbot Medical Inc. (NASDAQ:MBOT) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.6250.

Several equities analysts recently weighed in on the stock. Loop Capital set a $4.00 price target on shares of Microbot Medical in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th. Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Microbot Medical in a research report on Tuesday, April 14th.

Hedge Funds Weigh In On Microbot Medical

Several large investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC lifted its position in shares of Microbot Medical by 137.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,454,000 shares of the biotechnology company’s stock worth $4,435,000 after buying an additional 842,000 shares in the last quarter. Heights Capital Management Inc. bought a new position in shares of Microbot Medical during the 3rd quarter worth approximately $2,693,000. DNB Asset Management AS lifted its position in shares of Microbot Medical by 178.1% during the 4th quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock worth $1,355,000 after buying an additional 433,869 shares in the last quarter. Zacks Investment Management bought a new position in shares of Microbot Medical during the 3rd quarter worth approximately $33,000. Finally, American Century Companies Inc. bought a new position in shares of Microbot Medical during the 2nd quarter worth approximately $32,000. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Price Performance

Shares of NASDAQ MBOT opened at $1.86 on Monday. Microbot Medical has a fifty-two week low of $1.60 and a fifty-two week high of $4.67. The stock has a market cap of $124.94 million, a price-to-earnings ratio of -7.15 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. The firm’s 50-day simple moving average is $2.02 and its 200 day simple moving average is $2.16.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, research analysts anticipate that Microbot Medical will post -0.31 earnings per share for the current fiscal year.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.